Ortho-tag
Private Company
Total funding raised: $2.5M
Overview
Ortho-tag is pioneering a novel in-body communication and biosensing platform for medical implants. Its core technology, Volume Conduction Technology (VCT), provides a wireless, battery-free alternative to traditional RFID, enabling data exchange, implant identification, and diagnostic monitoring while being MRI-compatible and secure. The company targets applications in orthopedics and beyond, including post-surgical infection detection, in-vivo data storage, and controlled drug release, positioning itself at the intersection of smart implants and digital health.
Technology Platform
Proprietary Volume Conduction Technology (VCT) enabling wireless, battery-free in-body communication and data exchange for medical implants. It uses the body's conductive tissues to transmit signals, avoiding interference from metal or external RF sources (MRI compatible).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competition includes traditional RFID-based implant tracking solutions (which have interference limitations) and proprietary systems from large medtech firms (e.g., for specific smart implants). Ortho-tag's key differentiator is its MRI-compatible, battery-free, and interference-immune VCT platform, which, if proven, could become a new standard for in-body communication.